<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-12-52-59</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2564</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Современные критерии выбора эффективной пробиотико-терапии</article-title><trans-title-group xml:lang="en"><trans-title>Criteria for selection of probiotics for effective therapy of gut microbiota disorders</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Машарова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Masharova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Данилевская</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Danilevskaya</surname><given-names>N. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городская клиническая больница им. С.И. Спасокукоцкого Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.I. Spasokukotsky City Clinical Hospital С.И. of the Moscow Department of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>24</day><month>07</month><year>2018</year></pub-date><volume>0</volume><issue>12</issue><fpage>52</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Машарова А.А., Данилевская Н.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Машарова А.А., Данилевская Н.Н.</copyright-holder><copyright-holder xml:lang="en">Masharova A.A., Danilevskaya N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2564">https://www.med-sovet.pro/jour/article/view/2564</self-uri><abstract><p>В последнее время достигнут значительный прогресс в понимании микробиоты человека как экосистемы, выполняющей функции отдельного органа в макроорганизме. Все больше появляется данных по микробиому  – совокупности генов микроорганизмов, присутствующих в организме человека. Ухудшение экологии, изменение технологий производства пищевых продуктов, широкое использование антибиотиков приводят к серьезным нарушениям микробиоты человека, чаще всего в виде кишечного дисбиоза различной степени тяжести. Критерием успеха терапии дисбиоза является установление его причины и правильный выбор пробиотика, содержащего идентифицированные микроорганизмы с указанием рода, вида, штамма и их количественного состава. Целью данной статьи является обсуждение критериев рациональной пробиотической терапии и профилактики кишечного дисбиоза и ассоциированных с ним заболеваний. Необходимо учитывать, что лечение заболеваний, сопровождающихся дисбиозом, должно быть комплексным и включать в себя устранение причины заболевания, коррекцию питания, освобождение желудочно-кишечного тракта от патогенных возбудителей и их токсинов, а также восстановление состава и функциональной активности микробиоты. В восстановлении состава и функциональной активности микробиоты важную роль играют пробиотики. Согласно современным рекомендациям Всемирной гастроэнтерологической организации (ВГО) важным критерием эффективности пробиотических препаратов является определенное количество бактерий (KOE микроорганизмов), необходимое для достижения положительного эффекта.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Recently, the substantial progress has been made toward understanding the human microbiota as an ecosystem that functions as a separate organ in a macro-organism. More and more data on the microbiome as the aggregate of microorganism genes that reside on or within the human body appear. Deterioration of the environment, changes in food production technologies, widespread use of antibiotics result in serious human microbiota disorders, most often in the form of gut dysbiosis of varying severity. The investigation into the causes and the correct choice of a probiotic containing the identified microorganisms with the indication of genus, species, strain and their quantitative composition is the criterion for the success of dysbiosis therapy. The purpose of this article is to discuss the criteria for rational probiotic therapy and prevention of gut dysbiosis and associated diseases. It should be considered that the treatment of diseases accompanied by dysbiosis should be comprehensive and include the elimination of the cause of the disease, the correction of nutrition, the elimination of pathogenic agents and their toxins in the gastrointestinal tract, as well as the restoration of the microbiota composition and functional activity. Probiotics play an important role in restoring the composition and functional activity of microbiota. According to the current guidelines of the World Gastroenterological Organization (WGO), a certain quantity of bacteria (KOE of microorganisms) that is necessary to achieve a  positive effect is an important criterion for the efficacy of probiotic drugs.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>микробиота</kwd><kwd>кишечный дисбиоз</kwd><kwd>антибиотик-ассоциированная диарея</kwd><kwd>пробиотики (син. эубиотики)</kwd><kwd>международные рекомендации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>microbiota</kwd><kwd>gut dysbiosis</kwd><kwd>antibiotic-associated diarrhea</kwd><kwd>probiotics (syn. eubiotics)</kwd><kwd>international guidelines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Daniel R. The soil metagenomea rich resource for the discovery of novel natural products. Curr Opin Biotechnol, 2004, 15(3): 199-204.</mixed-citation><mixed-citation xml:lang="en">Daniel R. The soil metagenomea rich resource for the discovery of novel natural products. Curr Opin Biotechnol, 2004, 15(3): 199-204.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Qin J et al. A human gut microbial gene catalogue established by metagenomics sequencing. Nature, 2010, 464(7285): 59-65. doi:10.1038/nature08821.</mixed-citation><mixed-citation xml:lang="en">Qin J et al. A human gut microbial gene catalogue established by metagenomics sequencing. Nature, 2010, 464(7285): 59-65. doi:10.1038/nature08821.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schwiertz A, Rusch V. Microbiota of the Human Body Implications in Health and Disease, 2016, Advances in Experimental Medicine and Biology, (eBook). doi:10.1007/978-3-319-31248-4.</mixed-citation><mixed-citation xml:lang="en">Schwiertz A, Rusch V. Microbiota of the Human Body Implications in Health and Disease, 2016, Advances in Experimental Medicine and Biology, (eBook). doi:10.1007/978-3-319-31248-4.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science, 2001, 292: 1115–1118.</mixed-citation><mixed-citation xml:lang="en">Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science, 2001, 292: 1115–1118.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Panda S, Guarner F, Manichanh C. Structure and functions of the gut microbiome. Endocr Metab Immune Disord Drug Targets, 2014, 14(4): 290-299.</mixed-citation><mixed-citation xml:lang="en">Panda S, Guarner F, Manichanh C. Structure and functions of the gut microbiome. Endocr Metab Immune Disord Drug Targets, 2014, 14(4): 290-299.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pimentel M, Mathur R, Chang C. Gas and the microbiome. Curr Gastroenterol Rep, 2013, 15(12): 356. doi: 10.1007/s11894-013-0356-y.</mixed-citation><mixed-citation xml:lang="en">Pimentel M, Mathur R, Chang C. Gas and the microbiome. Curr Gastroenterol Rep, 2013, 15(12): 356. doi: 10.1007/s11894-013-0356-y.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Giles K, Pluvinage B, Boraston AB. Structure of a glycoside hydrolase family 50 enzyme from a subfamily that is enriched in human gut micro-biome bacteroidetes. Proteins, 2017, 85(1): 182-187. doi: 10.1002/prot.25189.</mixed-citation><mixed-citation xml:lang="en">Giles K, Pluvinage B, Boraston AB. Structure of a glycoside hydrolase family 50 enzyme from a subfamily that is enriched in human gut micro-biome bacteroidetes. Proteins, 2017, 85(1): 182-187. doi: 10.1002/prot.25189.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gloux K, Leclerc M, Iliozer H et al. Development of high-throughput phenotyping of metagenomic clones from the human gut microbiome for modulation of eukaryotic cell growth. Appl Environ Microbiol, 2007, 73(11): 3734-3737.</mixed-citation><mixed-citation xml:lang="en">Gloux K, Leclerc M, Iliozer H et al. Development of high-throughput phenotyping of metagenomic clones from the human gut microbiome for modulation of eukaryotic cell growth. Appl Environ Microbiol, 2007, 73(11): 3734-3737.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sudo N. Microbiome, HPA axis and production of endocrine hormones in the gut. Adv Exp Med Biol, 2014, 817: 177-194. doi: 10.1007/978-1-4939-0897-4-8.</mixed-citation><mixed-citation xml:lang="en">Sudo N. Microbiome, HPA axis and production of endocrine hormones in the gut. Adv Exp Med Biol, 2014, 817: 177-194. doi: 10.1007/978-1-4939-0897-4-8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf A, Moissl-Eichinger C, Perras A et al. The salivary microbiome as an indicator of carcino-genesis in patients with oropharyngeal squamous cell carcinoma: A pilot study. Sci Rep, 2017, 7(1): 5867. doi: 10.1038/s41598-017-06361-2.</mixed-citation><mixed-citation xml:lang="en">Wolf A, Moissl-Eichinger C, Perras A et al. The salivary microbiome as an indicator of carcino-genesis in patients with oropharyngeal squamous cell carcinoma: A pilot study. Sci Rep, 2017, 7(1): 5867. doi: 10.1038/s41598-017-06361-2.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Biagi P, Di Giulio A, Fiorilli A, Lorenzini A. Principi di nutrizione. Casa Editrice Ambrosia, 2014, p. 25.</mixed-citation><mixed-citation xml:lang="en">Biagi P, Di Giulio A, Fiorilli A, Lorenzini A. Principi di nutrizione. Casa Editrice Ambrosia, 2014, p. 25.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol, 2016 Aug 19, 14(8): e1002533.</mixed-citation><mixed-citation xml:lang="en">Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol, 2016 Aug 19, 14(8): e1002533.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Циммерман Я.С. Нерешенные и спорные проблемы современной гастроэнтерологии. М.: МЕДпресс-информ, 2013. 224 с</mixed-citation><mixed-citation xml:lang="en">Zimmerman YaS. Unsolved and controversial problems of modern gastroenterology. Moscow: MEDpress-inform, 2013. 224 p.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gill SR et al. Metagenomic analysis of the human distal gut microbiome. Science, 2006, 312: 1355–1359.</mixed-citation><mixed-citation xml:lang="en">Gill SR et al. Metagenomic analysis of the human distal gut microbiome. Science, 2006, 312: 1355–1359.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Беляева И.А., Бомбардирова Е.П., Митиш М.Д., Потехина Т.В., Харитонова Н.А. Онтогенез и дизонтогенез микробиоты кишечника у детей раннего возраста: триггерный механизм нарушений детского здоровья. Вопросы современной педиатрии, 2017, 16(1): 29-38</mixed-citation><mixed-citation xml:lang="en">Belyaeva IA, Bombardirova EP, Mitish MD, Potekhina TV, Kharitonova NA. Ontogenesis and dysontogene-sis of gut microbiota in young children: a trigger mechanism of child health disorders. Voprosy Sovremennoi Pediatrii, 2017, 16 (1): 29-38.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Guarner F, Sanders ME, Eliakim R et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2017.</mixed-citation><mixed-citation xml:lang="en">Guarner F, Sanders ME, Eliakim R et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2017.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Binns N. Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monographs Series. 2013. ILSI Europe, 32 р. ISBN: 9789078637394, ISSN: 2294–5490.</mixed-citation><mixed-citation xml:lang="en">Binns N. Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monographs Series. 2013. ILSI Europe, 32 р. ISBN: 9789078637394, ISSN: 2294–5490.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Machado M, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci, 2016, 17: 481.</mixed-citation><mixed-citation xml:lang="en">Machado M, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci, 2016, 17: 481.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Гасилина Т.В., Бельмер С.В. Современный взгляд на возможности коррекции кишечного микробиоценоза. РМЖ, 2017, 10: 726–729</mixed-citation><mixed-citation xml:lang="en">Gasilina TV, Belmer SV. Modern view on the possibility of correction of gut microbiocenosis. RMJ, 2017, 10: 726-729</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev, 2010, 9: 107–116.</mixed-citation><mixed-citation xml:lang="en">Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev, 2010, 9: 107–116.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Toward R, Montandon S, Walton G, Gibson GR: Effect of prebiotics on the human gut microbiota of elderly persons. Gut Microbes, 2012, 3: 57–60.</mixed-citation><mixed-citation xml:lang="en">Toward R, Montandon S, Walton G, Gibson GR: Effect of prebiotics on the human gut microbiota of elderly persons. Gut Microbes, 2012, 3: 57–60.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. Maturitas, 2013, 75: 44–50.</mixed-citation><mixed-citation xml:lang="en">Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. Maturitas, 2013, 75: 44–50.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Russell WR, Duncan SH, Flint HJ. The gut microbial metabolome: modulation of cancer risk in obese individuals. Proc NutrSoc, 2013, 72: 178–188.</mixed-citation><mixed-citation xml:lang="en">Russell WR, Duncan SH, Flint HJ. The gut microbial metabolome: modulation of cancer risk in obese individuals. Proc NutrSoc, 2013, 72: 178–188.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sebastián Domingo JJ. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017 Jun-Jul, 40(6): 417-429.</mixed-citation><mixed-citation xml:lang="en">Sebastián Domingo JJ. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017 Jun-Jul, 40(6): 417-429.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">OCEBM Levels of Evidence. https: www.cebm. net/2016/05/ocebm-levels-of-evidence/</mixed-citation><mixed-citation xml:lang="en">OCEBM Levels of Evidence. https: www.cebm. net/2016/05/ocebm-levels-of-evidence/</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Guarino A, Ashkenazi S, Gendrel D, et al. [European Society for Pediatric Gastroentero logy, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014]. Zhonghua Er Ke Za Zhi, 2015, 53: 499-509.</mixed-citation><mixed-citation xml:lang="en">Guarino A, Ashkenazi S, Gendrel D, et al. [European Society for Pediatric Gastroentero logy, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014]. Zhonghua Er Ke Za Zhi, 2015, 53: 499-509.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gottlieb T, Heather CS. Diarrhoea in adults (acute). BMJ Clin Evid, 2011, 2011.</mixed-citation><mixed-citation xml:lang="en">Gottlieb T, Heather CS. Diarrhoea in adults (acute). BMJ Clin Evid, 2011, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: From evidence base to clinical practice. Expert Opin Pharma-cother, 2012, 13: 17-26.</mixed-citation><mixed-citation xml:lang="en">Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: From evidence base to clinical practice. Expert Opin Pharma-cother, 2012, 13: 17-26.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol, 1996 Sep, 31(9): 887-91.</mixed-citation><mixed-citation xml:lang="en">Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol, 1996 Sep, 31(9): 887-91.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Аликеева Г.К., Ющук Н.Д., Сундуков А.В., Кожевникова Г.М. Диарея путешественников. http: www.lvrach.ru/2010/10/15435052.</mixed-citation><mixed-citation xml:lang="en">Alikeeva GK, Yushchuk ND, Sundukov AV, Kozhevnikova GМ. Travelers’ diarrhea. http: www.lvrach.ru/2010/10/15435052.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis, 1990. 12: S73–S79.</mixed-citation><mixed-citation xml:lang="en">Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis, 1990. 12: S73–S79.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wunderlich PF, Braun L, Fumagalli I, D’Apuzzo V, Heim F, Karly M, Lodi R, Politta G, Vonbank F, Zeltner L. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF 68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res, 1989 Jul-Aug, 17(4): 333-8.</mixed-citation><mixed-citation xml:lang="en">Wunderlich PF, Braun L, Fumagalli I, D’Apuzzo V, Heim F, Karly M, Lodi R, Politta G, Vonbank F, Zeltner L. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF 68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res, 1989 Jul-Aug, 17(4): 333-8.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Осипенко М.Ф., Бикбулатова Е.А., Холин С.И. Профилактика и лечение антибиотик-ассоциированной диареи: место пробиотиков. Медицинский совет, 2017, 11: 104-106</mixed-citation><mixed-citation xml:lang="en">Osipenko MF, Bikbulatova EA, Kholin SI. Preven tion and treatment of antibiotic-associated diarrhea: the place of probiotics. Meditsinsky Sovet, 2017, 11: 104-106.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Информационное письмо. Chr. Hansen A.S., Statement on safety of SF-68. / Information letter. Chr. Hansen AS, Statement on safety of SF-68.</mixed-citation><mixed-citation xml:lang="en">Information letter. Chr. Hansen AS, Statement on safety of SF-68.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Verholen F, Schori B, Haering G, Sanofi-Aventis (Suisse) SA, Vernier, Cerbios-Pharma SA, Barben go/ Lugano, Switzerland. JPGN, 2016 January, 62(1): 12.</mixed-citation><mixed-citation xml:lang="en">Verholen F, Schori B, Haering G, Sanofi-Aventis (Suisse) SA, Vernier, Cerbios-Pharma SA, Barben go/ Lugano, Switzerland. JPGN, 2016 January, 62(1): 12.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. October, 2011.</mixed-citation><mixed-citation xml:lang="en">World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. October, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Hamad A, Fragkos KC, Forbes A. A systematic review and meta-analysis of probiotics for the management of radiation induced bowel disease. Clin Nutr Edinb Scotl, 2013 Jun, 32(3): 353-60.</mixed-citation><mixed-citation xml:lang="en">Hamad A, Fragkos KC, Forbes A. A systematic review and meta-analysis of probiotics for the management of radiation induced bowel disease. Clin Nutr Edinb Scotl, 2013 Jun, 32(3): 353-60.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One, 2014, 9(11): e111030.</mixed-citation><mixed-citation xml:lang="en">Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One, 2014, 9(11): e111030.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Корниенко Е.А. с соавт. Пробиотики как способ повышения эффективности эрадикации Helicobacter pylori у детей. Детская гастроэнтерология и нутрициология, 2005, 13(3): 38-39. 40.Яковенко Э.П. с соавт. Влияние пробиотика Бифиформа на эффективность лечения инфекции Helicobacter pylori. Терапевти чес кий архив, 2006, 78(2): 21-26.</mixed-citation><mixed-citation xml:lang="en">Kornienko EA, et al. Probiotics as a way to increase the effectiveness of Helicobacter pylori eradication in children. Detskaya Gastro ehnterologiya i Nutritsiologiya, 2005, 13 (3): 38-39.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Валиева С.И. с соавт. Оценка эффективности пробиотической терапии у больных тяжелым ювенильным ревматоидным артритом в условиях антибактериальной терапии. Вопросы современной педиатрии, 2009, 8(4): 64-70.</mixed-citation><mixed-citation xml:lang="en">Yakovenko EP. et al. The effect of probiotic Bifiform on the effectiveness of treatment of Helicobacter pylori infection. Therapevtichesky Arkhiv, 2006, 78 (2): 21-26.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ручкина И.Н. с соавт. Роль микрофлоры тонкой кишки в развитии вторичной лактазной недостаточности и возможности ее лечения пробиотиками. Тер. Архив, 2013, 2: 21-26.</mixed-citation><mixed-citation xml:lang="en">Valieva SI, et al. Estimation of the effectiveness of probiotic therapy in patients with severe juvenile rheumatoid arthritis in the presence of antibacterial therapy. Voprosy Sovremennoy Pediatrii, 2009, 8 (4): 64-70.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Бондаренко В.М., Рыбальченко О.В. Оценка микробиоты и пробиотических штаммов с позиции научных технологий. Фарматека, 2016, 11: 21-33</mixed-citation><mixed-citation xml:lang="en">Ruchkina IN, et al. The role of the small intestine micro-flora in the development of secondary lactase deficiency and the possibility of its treatment with probiotics. Ter. Arkhiv, 2013, 2: 21-26.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Корнеева О.Н. Кишечная микробиота и ожирение. Патогенетические взаимосвязи и пути нормализации кишечной микрофлоры. Терапевтический архив, 2016, 88(9): 135-142.</mixed-citation><mixed-citation xml:lang="en">Bondarenko VM, Rybalchenko OV. Assessment of microbiota and probiotic strains from the standpoint of scientific technologies. Farmateka, 2016, 11: 21-33.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Drapkina OM, Korneeva ON. Gut microbiota and obesity. Pathogenetic relationships and ways to normalize the gut microflora. Terapevtichesky Arckiv, 2016, 88 (9): 135-142.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Korneeva ON. Gut microbiota and obesity. Pathogenetic relationships and ways to normalize the gut microflora. Terapevtichesky Arckiv, 2016, 88 (9): 135-142.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
